• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
165080 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  * g0 P: D) G) a  E* K

: ?4 A4 D8 q8 i2 N' i8 d
, f/ d8 W( b5 P0 G; [Sub-category:" H6 a% C. A4 e
Molecular Targets ' e' _! S+ J' p& f; H+ X
. `% Q& p8 p! l- ^) o

1 ^, n8 l5 R& m- f1 YCategory:
4 E7 p+ k2 `, N' q2 fTumor Biology
) R7 H9 W0 ]$ ?  u8 N. j/ _* r$ C# V4 }0 i

0 J: B5 s2 t, Z- E7 ~Meeting:
  s7 z3 {* C0 h: p2011 ASCO Annual Meeting   X& X" ]! f" @( i7 q) r

$ z: {% d) p) b9 P, w& X" Q9 r% r- G) \% I8 V0 V
Session Type and Session Title:1 b1 L* @7 W# M: L2 y9 l# Q3 A& V
Poster Discussion Session, Tumor Biology
% t4 m% M$ a, L; [; e% @2 t; e- r' Z0 Q4 _  N; i
0 r" O) w" f+ x5 Z+ ?
Abstract No:7 w. g' D) w$ a  d
10517 $ |' `$ b! L6 T
. M( b& Y. F0 C* I0 j

7 H% m& Q- O$ CCitation:% i/ `" y& `# {' i* {& x
J Clin Oncol 29: 2011 (suppl; abstr 10517)
- Z! c: {+ D$ Q9 `; W
. j6 d7 R/ @* F$ g3 c' _
9 N+ {! Z- w& M3 a, I8 k+ wAuthor(s):
* N" a1 X" ~. ZJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 7 d- U# ]( J( [7 J0 u0 E7 H
/ B( j( T( r9 K1 x' f: \- ]
. U# d. m3 i( w1 J1 Q
* X- x; f' E+ b. K8 \
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
) r" H0 p& |$ J( a% ^- ~
; P$ `/ Y2 e/ F$ @9 UAbstract Disclosures
2 L! h& [2 I( Z+ i
4 Q6 O5 r7 p% r3 p$ n' K  \7 eAbstract:
. }+ ]+ g& S& \+ s/ }* e0 H$ |6 `$ B( W2 E
' ]6 I$ c" L' R. L4 P3 M
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
/ K8 `8 B/ X" p. h7 {3 j) g/ k9 `4 \0 [
# `3 Q6 v/ i7 E3 D7 ~ 7 d# V3 L0 E: S; z6 ^: X% {9 L- N
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
4 {" U, d- N& d! g7 m1 ^2 k没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

; N. O8 h( c! W* ~: H% a6 ]化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
! s6 l& H! Y9 \+ M# m7 f* I7 X易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
+ y# Y$ P% G' t1 h7 `, V/ ?ALK一个指标医院要900多 ...
* B7 R4 h* V7 w5 B9 K5 |5 p7 I( ^
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?7 l$ h# O* B1 `# Y- i4 ^
3 r4 C  k% w! S9 ~  n5 w
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表